REPLIMUNE
LIVE

Serial Number

87322937

Owner

Replimune Limited

Attorney

Melanie Howard

Filing Date

Feb 2, 2017

Add to watchlist:

No watchlists yet
View on USPTO

REPLIMUNE Trademark

Serial Number: 87322937 • Registration: 5353768

REPLIMUNE is a trademark filed by Replimune Limited on February 2, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Replimune Limited (14 trademarks)

69 Innovation Dr., Milton Park, Abingdon
Oxfordshire OX144RQ , GB

Entity Type: 99

Trademark Details

Filing Date

February 2, 2017

Registration Date

December 12, 2017

Published for Opposition

September 26, 2017

Goods & Services

Biological preparations in the nature of viruses for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; viruses for the treatment of cancer and tumors; viruses for inducing immune response for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceutical preparations and pharmaceutical substances for the treatment of [ infectious, ]oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceutical preparations and pharmaceutical substances used for the prevention and treatment of cancer and tumors; pharmaceuticals, namely, [ anti-infectives ] for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response for the treatment of cancer and tumors; vaccines; immunotherapy products, namely, pharmaceuticals for the treatment of cancer, tumors, [ infectious, ] oncological [ , autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system ] diseases and disorders

[ Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services regarding research and development in the fields of pharmaceuticals, vaccines and medicines ]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Aug 26, 2024 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Aug 26, 2024 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 12, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Dec 6, 2023 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 12, 2022 REM1
CORRECTION UNDER SECTION 7 - PROCESSED
Sep 4, 2020 COC.
CORRECTION UNDER SECTION 7 - PROCESSED
Sep 20, 2018 COC.
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Sep 10, 2018 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Apr 11, 2018 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 28, 2018 APRE
TEAS SECTION 7 REQUEST RECEIVED
Feb 20, 2018 ES7R
REGISTERED-PRINCIPAL REGISTER
Dec 12, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 26, 2017 NPUB
PUBLISHED FOR OPPOSITION
Sep 26, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 6, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 19, 2017 CNSA
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Aug 18, 2017 AMPX
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 14, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 14, 2017 CRFA
ASSIGNED TO LIE
Aug 14, 2017 ALIE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 4, 2017 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 4, 2017 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 19, 2017 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 11, 2017 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 4, 2017 GNRN
NON-FINAL ACTION E-MAILED
May 4, 2017 GNRT
NON-FINAL ACTION WRITTEN
May 4, 2017 CNRT
ASSIGNED TO EXAMINER
Apr 27, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 7, 2017 NWOS
NEW APPLICATION ENTERED
Feb 6, 2017 NWAP